Bevacizumab in HER2-negative inflammatory breast cancer

Oncoscience. 2016 Nov 15;3(11-12):297-298. doi: 10.18632/oncoscience.324. eCollection 2016.

Authors

François Bertucci¹, Anthony Goncalves¹, Patrice Viens¹

Affiliation

¹ Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

No abstract available

Keywords: VEGF; bevacizumab; inflammatory breast cancer; pathological complete response; survival.

Publication types

Editorial